Müllerian inhibiting substance induces apoptosis of human endometrial stromal cells in endometriosis

Journal of Clinical Endocrinology and Metabolism

Volumn 97, Issue 9, 2012, Pages 3224-3230

  Namkung, Jeong ^a   Song, Jae Yen ^a   Jo, Hyun Hee ^a   Kim, Mee Ran ^a   Lew, Young Oak ^a   Donahoe, Patricia K ^b   MacLaughlin, David T ^b   Kim, Jang Heub ^b  

^a The Catholic University of Korea   (South Korea)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LIPOCORTIN 5; MUELLERIAN INHIBITING FACTOR; MUELLERIAN INHIBITING FACTOR RECEPTOR TYPE II; PROTEIN P107; PROTEIN P130; PROTEIN P16; REGULATOR PROTEIN; TRANSCRIPTION FACTOR E2F1; UNCLASSIFIED DRUG; ANTI MULLERIAN HORMONE RECEPTOR; ANTI-MULLERIAN HORMONE RECEPTOR; RECEPTOR; TETRAZOLIUM; THIAZOLE DERIVATIVE; THIAZOLYL BLUE; TRANSCRIPTION FACTOR E2F; TRANSFORMING GROWTH FACTOR BETA RECEPTOR;

APOPTOSIS; ARTICLE; CELL CULTURE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CELL GROWTH; CELL PROLIFERATION; CELL VIABILITY; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOMETRIAL STROMA CELL; ENDOMETRIOSIS; ENDOMETRIUM CELL; ENZYME INHIBITION; EVISCERATION; FEMALE; GROWTH INHIBITION; HORMONE ACTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; OVARY CYST; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN TARGETING; STROMA CELL; BIOSYNTHESIS; CELL CYCLE; CYTOLOGY; DRUG EFFECT; ENDOMETRIUM; GENETICS; METABOLISM; PATHOLOGY; TUMOR CELL LINE; UTERINE CERVIX TUMOR; WESTERN BLOTTING;

ANNEXIN A5; ANTI-MULLERIAN HORMONE; APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE; CELL LINE, TUMOR; CELLS, CULTURED; E2F TRANSCRIPTION FACTORS; ENDOMETRIOSIS; ENDOMETRIUM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; RECEPTORS, PEPTIDE; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; RETINOBLASTOMA-LIKE PROTEIN P107; RETINOBLASTOMA-LIKE PROTEIN P130; STROMAL CELLS; TETRAZOLIUM SALTS; THIAZOLES; UTERINE CERVICAL NEOPLASMS;

EID: 84866142758     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2012-1538     Document Type: Article

References (35)

1. Bulletti C, Coccia ME, Battistoni S, Borini A 2010 Endometriosis and infertility. J Assist Reprod Genet 27:441-447
2. Vlahos NF, Kalampokas T, Fotiou S 2010 Endometriosis and ovarian cancer: a review. Gynecol Endocrinol 26:213-219
3. Dufournet C, Uzan C, Fauvet R, Cortez A, Siffroi JP, Daraï E 2006 Expression of apoptosis-related proteins in peritoneal, ovarian and colorectal endometriosis. J Reprod Immunol 70:151-162 (Pubitemid 43669096)
4. Nasu K, Nishida M, Kawano Y, Tsuno A, Abe W, Yuge A, Takai N, Narahara H 2011 Aberrant expression of apoptosis-related molecules in endometriosis: a possible mechanism underlying the pathogenesis of endometriosis. Reprod Sci 18:206-218
5. Meresman GF, Vighi S, Buquet RA, Contreras-Ortiz O, Tesone M, Rumi LS 2000 Apoptosis and expression of Bcl-2 and Bax in eutopic endometrium from women with endometriosis. Fertil Steril 74:760-766
6. Béliard A, Noël A, Foidart JM 2004 Reduction of apoptosis and proliferation in endometriosis. Fertil Steril 82:80-85
7. Szymanowski K 2007 Apoptosis pattern in human endometrium in women with pelvic endometriosis. Eur J Obstet Gynecol Reprod Biol 132:107-110 (Pubitemid 46635960)
8. Nasu K, Nishida M, Ueda T, Takai N, Bing S, Narahara H, Miyakawa I 2005 Bufalin induces apoptosis and the G0/G1 cell cycle arrest of endometriotic stromal cells: a promising agent for the treatment of endometriosis. Mol Hum Reprod 11:817-823 (Pubitemid 43205490)
9. Nishida M, Nasu K, Ueda T, Yuge A, Takai N, Narahara H 2006 Beta-hydroxyisovalerylshikonin induces apoptosis and G0/G1 cell-cycle arrest of endometriotic stromal cells: a preliminary in vitro study. Hum Reprod 21:2850-2856 (Pubitemid 44566997)
10. MacLaughlin DT, Teixeira J, Donahoe PK 2001 Perspective: reproductive tract development: new discoveries and future directions. Endocrinology 142:2167-2172 (Pubitemid 32473067)
11. Baarends WM, van Helmond MJ, Post M, van der Schoot PJ, Hoogerbrugge JW, de Winter JP, Uilenbroek JT, Karels B, Wilming LG, Meijers JH, Themmen AP, Grootegoed JA 1994 A novel member of the transmembrane serine/threonine kinase receptor family is specifically expressed in the gonads and in mesenchymal cells adjacent to the mullerian duct. Development 120:189-197
12. di Clemente N, Wilson C, Faure E, Boussin L, Carmillo P, Tizard R, Picard JY, Vigier B, Josso N, Cate R 1994 Cloning, expression, and alternative splicing of the receptor for anti-Mullerian hormone. Mol Endocrinol 8:1006-1020
13. Imbeaud S, Faure E, Lamarre I, Mattéi MG, di Clemente N, Tizard R, Carré-Eusèbe D, Belville C, Tragethon L, Tonkin C, Nelson J, McAuliffe M, Bidart JM, Lababidi A, Josso N, Cate RL, Picard JY 1995 Insensitivity to anti-mullerian hormone due to a mutation in the human anti-mullerian hormone receptor. Nat Genet 11:382-388
14. Mishina Y, Whitworth DJ, Racine C, Behringer RR 1999 High specificity of Mullerian-inhibiting substance signaling in vivo. Endocrinology 140:2084-2088 (Pubitemid 30636446)
15. Ha TU, Segev DL, Barbie D, Masiakos PT, Tran TT, Dombkowski D, Glander M, Clarke TR, Lorenzo HK, Donahoe PK, Maheswaran S 2000 Mullerian inhibiting substance inhibits ovarian cell growth through an Rb-independent mechanism. J Biol Chem 275:37101-37109 (Pubitemid 32002128)
16. Barbie TU, Barbie DA, MacLaughlin DT, Maheswaran S, Donahoe PK 2003 Mullerian Inhibiting Substance inhibits cervical cancer cell growth via a pathway involving p130 and p107. Proc Natl Acad Sci USA 100:15601-15606 (Pubitemid 38021036)
17. Gupta V, Carey JL, Kawakubo H, Muzikansky A, Green JE, Donahoe PK, MacLaughlin DT, Maheswaran S 2005 Mullerian inhibiting substance suppresses tumor growth in the C3(1)T antigen transgenic mouse mammary carcinoma model. Proc Natl Acad Sci USA 102:3219-3224 (Pubitemid 40328026)
18. Segev DL, Ha TU, Tran TT, Kenneally M, Harkin P, Jung M, MacLaughlin DT, Donahoe PK, Maheswaran S 2000 Mullerian inhibiting substance inhibits breast cancer cell growth through an NFκB-mediated pathway. J Biol Chem 275:28371-28379
19. MacLaughlin DT, Donahoe PK 2010 Mullerian inhibiting substance/anti- Mullerian hormone: a potential therapeutic agent for human ovarian and other cancers. Future Oncol 6:391-405
20. Renaud EJ, MacLaughlin DT, Oliva E, Rueda BR, Donahoe PK 2005 Endometrial cancer is a receptor-mediated target for Mullerian inhibiting substance. Proc Natl Acad Sci USA 102:111-116 (Pubitemid 40094437)
21. Gaetje R, Kotzian S, Herrmann G, Baumann R, Starzinski-Powitz A 1995 Invasiveness of endometriotic cells in vitro. Lancet 346:1463-1464
22. Jimbo H, Hitomi Y, Yoshikawa H, Yano T, Momoeda M, Sakamoto A, Tsutsumi O, Taketani Y, Esumi H 1997 Evidence for monoclonal expansion of epithelial cells in ovarian endometrial cysts. Am J Pathol 150:1173-1178 (Pubitemid 27152635)
23. Nishida M, Nasu K, Ueda T, Fukuda J, Takai N, Miyakawa I 2005 Endometriotic cells are resistant to interferon-γ-induced cell growth inhibition and apoptosis: a possible mechanism involved in the pathogenesis of endometriosis. Mol Hum Reprod 11:29-34 (Pubitemid 40331000)
24. Bergqvist A 2000 A comparative study of the acceptability and effect of goserelin and nafarelin on endometriosis. Gynecol Endocrinol 14:425-432 (Pubitemid 32165452)
25. Wang J, Dicken C, Lustbader JW, Tortoriello DV 2009 Evidence for a Müllerian-inhibiting substance autocrine/paracrine system in adult human endometrium. Fertil Steril 91:1195-1203
26. Song JY, Chen KY, Kim SY, Kim MR, Ryu KS, Cha JH, Kang CS, MacLaughlin DT, Kim JH 2009 The expression of Müllerian inhibiting substance/anti- Müllerian hormone type II receptor protein and mRNA in benign, borderline and malignant ovarian neoplasia. Int J Oncol 34:1583-1591
27. Hwang SJ, Suh MJ, Yoon JH, Kim MR, Ryu KS, Nam SW, Donahoe PK, Maclaughlin DT, Kim JH 2011 Identification of characteristic molecular signature of Mullerian inhibiting substance in human HPV-related cervical cancer cells. Int J Oncol 39:811-820
28. Fuller Jr AF, Budzik GP, Krane IM, Donahoe PK 1984 Müllerian inhibiting substance inhibition of a human endometrial carcinoma cell line xenografted in nude mice. Gynecol Oncol 17:124-132 (Pubitemid 14176298)
29. Masiakos PT, MacLaughlin DT, Maheswaran S, Teixeira J, Fuller Jr AF, Shah PC, Kehas DJ, Kenneally MK, Dombkowski DM, Ha TU, Preffer FI, Donahoe PK 1999 Human ovarian cancer, cell lines, and primary ascites cells express the human Mullerian inhibiting substance (MIS) type II receptor, bind, and are responsive to MIS. Clin Cancer Res 5:3488-3499
30. Stephen AE, Pearsall LA, Christian BP, Donahoe PK, Vacanti JP, MacLaughlin DT 2002 Highly purified müllerian inhibiting substance inhibits human ovarian cancer in vivo. Clin Cancer Res 8:2640-2646 (Pubitemid 34856352)
31. Segev DL, Hoshiya Y, Stephen AE, Hoshiya M, Tran TT, MacLaughlin DT, Donahoe PK, Maheswaran S 2001 Mullerian inhibiting substance regulates NFκB signaling and growth of mammary epithelial cells in vivo. J Biol Chem 276:26799-26806
32. Lane DP 1992 Cancer. p53, guardian of the genome. Nature 358:15-16
33. Levine AJ 1997 p53, the cellular gatekeeper for growth and division. Cell 88:323-331 (Pubitemid 27131374)
34. Schwarz JK, Bassing CH, Kovesdi I, Datto MB, Blazing M, George S, Wang XF, Nevins JR 1995 Expression of the E2F1 transcription factor overcomes type β transforming growth factor-mediated growth suppression. Proc Natl Acad Sci USA 92:483-487
35. Sun P, Dong P, Dai K, Hannon GJ, Beach D 1998 p53-independent role of MDM2 in TGF-beta1 resistance. Science 282:2270-2272 (Pubitemid 29004078)